Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Adrenocortical Insufficiency Associated with Long-term High-dose Fosfestrol Therapy for Prostatic Carcinoma
Hiroshi IIDAIchiro MIYAMOTOYatsugi NODAMasaru SAWAKIYukihiro NAGAI
Author information
JOURNAL FREE ACCESS

1999 Volume 38 Issue 10 Pages 804-807

Details
Abstract
A 59-year-old man was admitted to our hospital because of muscular pain, weakness, and anorexia. He had been treated with 600 mg/day of fosfestrol, a synthetic estrogen, for 10 years for prostatic carcinoma. Endocrinological studies demonstrated adrenocortical insufficiency due to inadequate ACTH secretion. After initiation of glucocorticoid replacement therapy, his symptoms subsided rapidly. To our knowledge, an association between estrogenic agents, including fosfestrol, and secondary adrenocortical insufficiency has not been previously reported. Physicians who treat patients with long-term and high-dose strong estrogenic agents should be cautious about the possible emergence of secondary adrenocortical insufficiency.
(Internal Medicine 38: 804-807, 1999)
Content from these authors
© The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top